Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder-Reference-Cited by-同舟云学术

Cardiovascular safety of medication treatments for attention-deficit/hyperactivity disorder

Published:2009-04 Issue:2 Volume:76 Page:198-203
ISSN:0027-2507
Container-title:Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine
language:en
Short-container-title:Mt Sinai J Med

Author:

Newcorn Jeffrey H.,Donnelly Craig

Publisher

Wiley

Subject

General Medicine

Reference13 articles.

1. Cardiovascular monitoring of children and adolescents with heart disease receiving medications for attention deficit/hyperactivity disorder: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing;Vetter;Circulation,2008

2. Cardiovascular monitoring of children and adolescents receiving psychotropic drugs: a statement for healthcare professionals from the Committee on Congenital Cardiac Defects, Council on Cardiovascular Disease in the Young, American Heart Association;Gutgesell;Circulation,1999

3. US Food and Drug Administration. Drug Safety and Risk Management Advisory Committee report. Available at: http://www.fda.gov/ohrms/dockets/ac/cder06.html#drugsafetyriskmgmt. Accessed May 2008.

4. Villalba L. Safety review: sudden death with drugs used to treat ADHD. February 28, 2006. Available at: http://www.fda.gov/ohrms/dockets/ac/06/briefing/2006-4210b_07_01_safetyreview.pdf. Accessed May 2008.

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Adverse effects of stimulant medications in children and adolescents: focus on cardiovascular issues;International Journal of Adolescent Medicine and Health;2019-06-26

2. A randomized controlled laboratory study on the long-term effects of methylphenidate on cardiovascular function and structure in rhesus monkeys;Pediatric Research;2018-12-17

3. Pharmacotherapy for Child and Adolescent Attention-deficit Hyperactivity Disorder;Pediatric Clinics of North America;2011-02

4. Current awareness: Pharmacoepidemiology and drug safety;Pharmacoepidemiology and Drug Safety;2009-09-29